Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea.

导出 LinkOut

翻译打印收藏纠错

作者： Sun In,Hong ^[1] ; Byung-Han,Ryu ^[1] ; Kyung-Wook,Hong ^[2] ; In-Gyu,Bae ^[2] ; Oh-Hyun,Cho ^[3]

作者单位： Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea. ^[1] Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. ^[2] Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Korea. ^[3] Department of Internal Medicine, Gyeongsangnam-do Masan Medical Center, Changwon, Korea. zenmd@naver.com. ^[4]

关键词 COVID-19 Monoclonal antibody Regdanvimab

DOI 10.3947/ic.2021.0143

PMID 35384423

发布时间 2022-08-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Infection & chemotherapy

2022年54卷1期

114-124页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea.

Infection & chemotherapy

相似文献

Infection & chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea.

Infection & chemotherapy

相似文献

Infection & chemotherapy

相关期刊

检索历史清除